Akhu Therapeutics, Inc.

  Akhu is advancing innovative therapeutics to treat mood and anxiety disorders, which increase susceptibility to mortality and disability for 350 million people worldwide. Akhu’s approach is designed to outperform antidepressants and anxiolytics by blocking MC5R signaling.   
Team: 
Victor Hruby
Robert Gillies
Joseph Vagner
David Morse